|
EP2857036B1
(en)
|
2003-01-31 |
2016-12-21 |
Mount Sinai School of Medicine of New York University |
Combination therapy for treating protein deficiency disorders
|
|
PL2533050T6
(pl)
|
2006-05-16 |
2016-05-31 |
Amicus Therapeutics Inc |
Możliwości leczenia choroby Fabry'ego
|
|
US9999618B2
(en)
|
2007-04-26 |
2018-06-19 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
|
EP2946785B1
(en)
|
2008-02-12 |
2018-10-24 |
Amicus Therapeutics, Inc. |
Method to predict response to pharmacological chaperone treatment of diseases
|
|
US8540985B2
(en)
|
2008-06-26 |
2013-09-24 |
Orphazyme Aps |
Use of Hsp70 as a regulator of enzymatic activity
|
|
WO2010048532A1
(en)
|
2008-10-24 |
2010-04-29 |
Amicus Therapeutics, Inc. |
Multiple compartment dosing model
|
|
WO2010056746A1
(en)
*
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
BRPI1010517A2
(pt)
*
|
2009-04-09 |
2017-01-31 |
Amicus Therapeutics Inc |
métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
|
|
GB0906159D0
(en)
*
|
2009-04-09 |
2009-05-20 |
Summit Corp Plc |
Drug combination for the treatment of proteostatic diseases
|
|
KR101880411B1
(ko)
|
2009-10-19 |
2018-07-19 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
|
|
US9044437B2
(en)
*
|
2009-10-19 |
2015-06-02 |
Amicus Therapeutics, Inc. |
Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
|
|
SI2995306T1
(sl)
|
2009-10-19 |
2019-04-30 |
Amicus Therapeutics, Inc. |
Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
|
|
AU2010311515B2
(en)
*
|
2009-10-27 |
2014-02-20 |
Erytech Pharma |
Composition to induce specific immune tolerance
|
|
WO2011063048A2
(en)
*
|
2009-11-17 |
2011-05-26 |
Baylor Research Institute |
Urinary triaosylceramide (gb3) as a marker of cardiac disease
|
|
CA3140959A1
(en)
*
|
2009-11-27 |
2011-06-03 |
Genzyme Corporation |
An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
|
|
SI2638152T1
(sl)
*
|
2010-11-08 |
2016-12-30 |
Amicus Therapeutics, Inc. |
Variantni in rekombinantni proteini beta-glukocerebrozidaze s povišano stabilnostjo in povišano ohranjeno katalitično aktivnostjo
|
|
RU2013125923A
(ru)
|
2010-11-30 |
2015-01-10 |
Орфазиме Апс |
СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
|
|
SG10201604757RA
(en)
*
|
2011-03-11 |
2016-08-30 |
Amicus Therapeutics Inc |
Dosing regimens for the treatment of fabry disease
|
|
EP2533051A1
(en)
*
|
2011-06-06 |
2012-12-12 |
Centogene GmbH |
Method for the diagnosis of Gaucher's disease
|
|
KR20230066482A
(ko)
|
2012-03-07 |
2023-05-15 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
CA2868459A1
(en)
|
2012-03-27 |
2013-10-03 |
Amicus Therapeutics, Inc. |
Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
|
|
SMT202100136T1
(it)
*
|
2012-05-03 |
2021-05-07 |
Amicus Therapeutics Inc |
Regimi posologici per il trattamento della malattia di pompe
|
|
US10155027B2
(en)
|
2012-07-17 |
2018-12-18 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
|
|
WO2014014938A1
(en)
|
2012-07-17 |
2014-01-23 |
Amicus Therapeutics, Inc. |
Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
|
|
US9675627B2
(en)
*
|
2014-04-14 |
2017-06-13 |
Amicus Therapeutics, Inc. |
Dosing regimens for treating and/or preventing cerebral amyloidoses
|
|
US10709700B2
(en)
|
2014-09-15 |
2020-07-14 |
Orphazyme A/S |
Arimoclomol formulation
|
|
CN114540327B
(zh)
|
2014-09-30 |
2026-03-24 |
阿米库斯治疗学公司 |
具有增强的碳水化合物的高强度酸性α-葡糖苷酶
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
US10179128B2
(en)
*
|
2015-08-31 |
2019-01-15 |
Amicus Therapeutics, Inc. |
Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
|
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
KR20250007693A
(ko)
|
2015-12-30 |
2025-01-14 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병 치료용의 강화된 산 알파-글루코시다제
|
|
JP6438421B2
(ja)
*
|
2016-02-17 |
2018-12-12 |
ファナック株式会社 |
電動機のステータ
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
AU2017239641A1
(en)
|
2016-03-30 |
2018-10-18 |
Amicus Therapeutics, Inc. |
Formulations comprising recombinant acid alpha-glucosidase
|
|
EP3442530A1
(en)
|
2016-04-13 |
2019-02-20 |
Orphazyme A/S |
Heat shock proteins and cholesterol homeostasis
|
|
KR20210059796A
(ko)
|
2016-04-29 |
2021-05-25 |
오르파짐 에이/에스 |
글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
|
|
CA3023092A1
(en)
|
2016-05-03 |
2017-11-09 |
Sqz Biotechnologies Company |
Intracellular delivery of biomolecules to induce tolerance
|
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
CN110573492A
(zh)
|
2017-04-25 |
2019-12-13 |
阿米库斯治疗学公司 |
用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物
|
|
SMT202300187T1
(it)
|
2017-05-15 |
2023-07-20 |
Amicus Therapeutics Inc |
Alfa-glucosidasi acida umana ricombinante
|
|
RS65230B1
(sr)
|
2017-05-30 |
2024-03-29 |
Amicus Therapeutics Inc |
Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega
|
|
CA3224546C
(en)
|
2017-05-30 |
2026-02-24 |
Amicus Therapeutics, Inc. |
Use of migalastat in the treatment of fabry patients
|
|
KR20200128676A
(ko)
|
2018-02-06 |
2020-11-16 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
|
|
US12594268B2
(en)
|
2018-08-20 |
2026-04-07 |
Amicus Therapeutics, Inc. |
Methods of treating Fabry disease in patients having a mutation in the GLA gene
|
|
US20220025065A1
(en)
*
|
2018-12-10 |
2022-01-27 |
Denali Therapeutics Inc. |
Lysosomal storage disorder biomarkers and methods of use thereof
|
|
MX2021015352A
(es)
*
|
2019-06-11 |
2022-04-06 |
Amicus Therapeutics Inc |
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
|
|
KR20220044560A
(ko)
|
2019-08-07 |
2022-04-08 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
|
|
KR20230128462A
(ko)
|
2020-11-19 |
2023-09-05 |
제브라 덴마크 에이/에스 |
아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
|
|
US11623916B2
(en)
|
2020-12-16 |
2023-04-11 |
Amicus Therapeutics, Inc. |
Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
|